Definitive Healthcare (DH) Expected to Release Earnings on Thursday

Definitive Healthcare (NASDAQ:DH) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Definitive Healthcare to announce earnings of $0.04 per share and revenue of $54.58 million for the quarter. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Monday, August 10th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The company had revenue of $55.20 million during the quarter, compared to the consensus estimate of $55.47 million. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%. On average, analysts expect Definitive Healthcare to post $0.06 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

Definitive Healthcare Price Performance

Definitive Healthcare stock opened at $1.17 on Wednesday. The stock’s 50 day moving average is $1.00 and its 200 day moving average is $1.08. Definitive Healthcare has a one year low of $0.61 and a one year high of $3.00. The firm has a market cap of $124.90 million, a P/E ratio of -0.73, a P/E/G ratio of 13.94 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. BTIG Research restated a “neutral” rating on shares of Definitive Healthcare in a report on Friday, September 4th. Morgan Stanley reduced their price objective on shares of Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $1.00 price objective on shares of Definitive Healthcare in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $1.47.

Definitive Healthcare Company Profile

Definitive Healthcare Corp. (NASDAQ: DH) provides data, analytics and commercial intelligence solutions for the healthcare industry. Its platform is designed to help organizations understand healthcare markets, identify business opportunities and make data-driven decisions.

The company serves pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, hospitals and health systems, and other healthcare services organizations. Its offerings include information on healthcare providers and organizations, market intelligence, sales and marketing analytics, clinical trial insights, and tools that support commercial planning, market access and customer engagement.

Definitive Healthcare was founded in 2011 and became a publicly traded company in 2021.